ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Tuesday, November 14, 2023

9:00AM-11:00AM: Abstract Number: 1767

TNF-α Utilizes the TWEAK/Fn-14 Axis in Human Rheumatoid Arthritis Synovial Fibroblasts to Induce Inflammation

(1734–1775) RA – Etiology and Pathogenesis Poster

9:00AM-11:00AM: Abstract Number: 1808

Tobacco Smoking Reduces the Incidence and Delays the Progression of Knee Osteoarthritis: 10-year Retrospective Cohort Study Based on Korea National Health Insurance Service-Health Screening Database

(1796–1826) Epidemiology & Public Health Poster III

9:00AM-11:00AM: Abstract Number: 2410

Tocilizumab versus Methotrexate in Giant Cell Arteritis: A Retrospective Study to Compare Efficacy and Rapidity of These Steroid-sparing Agents in GCA Patients

(2387–2424) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

9:00AM-11:00AM: Abstract Number: 1962

Toll-Like Receptor 7/8 Activation of Immune and Non-Immune Cells in Muscle by RNA-Containing Immune Complexes Can Contribute to Inflammation and the Pathogenesis of Myositis

(1945–1972) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster III

9:00AM-11:00AM: Abstract Number: 2374

Torque Teno Virus as a Potential Biomarker for Assessment of Immunocompetence in Patients with ANCA-associated Vasculitis

(2370–2386) Vasculitis – ANCA-Associated Poster III: Biomarkers & Renal Outcomes

9:00AM-11:00AM: Abstract Number: 1887

Total-body PET Quantitative Biomarkers Reveal Key Differences in Enthesitis Between Rheumatoid and Psoriatic Arthritis Patients

(1862–1894) Imaging of Rheumatic Diseases Poster II

9:00AM-11:00AM: Abstract Number: 2063

Training to Increase Minority Enrollment in Lupus Clinical Trials with CommunitY Engagement (TIMELY): Assessing Behavioral Predictors of Clinical Trial Referrals Among Healthcare Providers

(2061–2088) Professional Education Poster

9:00AM-11:00AM: Abstract Number: 2023

Transition Readiness over Time in a Rheumatology Transition Clinic

(2019–2038) Patient Outcomes, Preferences, & Attitudes Poster III

9:00AM-11:00AM: Abstract Number: 1904

Treat-to-Target in RA Clinical Practice: Global Evidence of Practice Gaps and Educational Needs

(1895–1912) Measures & Measurement of Healthcare Quality Poster II

9:00AM-11:00AM: Abstract Number: 2045

Treatment Response in a Cohort of Pediatric Patients with Autosomal Dominant Neovascular Inflammatory Vitreoretinopathy (ADNIV)

(2039–2060) Pediatric Rheumatology – Clinical Poster III: Potpourri

9:00AM-11:00AM: Abstract Number: 2154

Two-Year Persistence of First-Line Biological or JAK Inhibitor Treatment in Patients with Long-Standing Rheumatoid Arthritis and Failure of Triple Therapy with Synthetic DMARDs

(2141–2176) RA – Treatments Poster III

9:00AM-11:00AM: Abstract Number: 2243

Ultrasound Enthesitis Responsiveness versus Clinical Enthesitis Responsiveness: Week 52 Results of an Exploratory Analysis from a Phase 3b Study in Patients with Psoriatic Arthritis

(2227–2256) Spondyloarthritis Including Psoriatic Arthritis – Treatment: SpA Poster III

9:00AM-11:00AM: Abstract Number: 2066

Ultrasound Guided Synovial Biopsy Course: Achievement of Learner Self Efficacy

(2061–2088) Professional Education Poster

9:00AM-11:00AM: Abstract Number: 2399

Ultrasound Is Comparable to Computed Tomography Angiography in Identifying Aortic Aneurysms in Patients with Giant Cell Arteritis

(2387–2424) Vasculitis – Non-ANCA-Associated & Related Disorders Poster III

9:00AM-11:00AM: Abstract Number: 1755

Unique Pattern of Cadherin 6 Localization in Fibroblast-Like Synoviocytes

(1734–1775) RA – Etiology and Pathogenesis Poster

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].